Free Trial
NASDAQ:TARA

Protara Therapeutics (TARA) Stock Price, News & Analysis

Protara Therapeutics logo
$3.22 +0.19 (+6.27%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$3.22 0.00 (0.00%)
As of 08:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Protara Therapeutics Stock (NASDAQ:TARA)

Key Stats

Today's Range
$3.00
$3.23
50-Day Range
$2.78
$3.58
52-Week Range
$1.60
$10.48
Volume
357,934 shs
Average Volume
796,763 shs
Market Capitalization
$124.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50
Consensus Rating
Buy

Company Overview

Protara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

TARA MarketRank™: 

Protara Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 728th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Protara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Protara Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Protara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($3.32) to ($3.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Protara Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Protara Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Protara Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Protara Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.23% of the float of Protara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Protara Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Protara Therapeutics has recently increased by 0.92%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Protara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Protara Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.23% of the float of Protara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Protara Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Protara Therapeutics has recently increased by 0.92%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Protara Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • Search Interest

    Only 5 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Protara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.40% of the stock of Protara Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 38.13% of the stock of Protara Therapeutics is held by institutions.

  • Read more about Protara Therapeutics' insider trading history.
Receive TARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TARA Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Protara Therapeutics, Inc. (TARA) - Yahoo Finance
See More Headlines

TARA Stock Analysis - Frequently Asked Questions

Protara Therapeutics' stock was trading at $5.28 at the beginning of 2025. Since then, TARA shares have decreased by 39.0% and is now trading at $3.22.

Protara Therapeutics, Inc. (NASDAQ:TARA) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.18.

Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Digital Turbine (APPS), SoFi Technologies (SOFI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/08/2025
Today
7/10/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TARA
CIK
1359931
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$12.00
Potential Upside/Downside
+536.6%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.60 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.77 per share
Price / Book
0.68

Miscellaneous

Free Float
35,341,000
Market Cap
$124.23 million
Optionable
Optionable
Beta
1.35
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:TARA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners